Remus Pharmaceuticals (NSE:REMUS) Other Stockholders Equity: ₹3,392 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:REMUS Remus Pharmaceuticals Ltd NSE:REMUS
53 GF Score
Price ₹739.55
GF Value ₹2,071.36
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Remus Pharmaceuticals Other Stockholders Equity?

Remus Pharmaceuticals NSE:REMUS +3.02% 53 Other Stockholders Equity is ₹3,392 Mil as of Mar. 2026. GuruFocus rates NSE:REMUS with a GF Score™ of 53/100 and a GF Value™ of ₹2,071.36 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Remus Pharmaceuticals's Other Stockholders Equity for the quarter that ended in Mar. 2026 was ₹3,392 Mil.

Remus Pharmaceuticals's quarterly Other Stockholders Equity increased from Mar. 2025 (₹1,424 Mil) to Sep. 2025 (₹2,952 Mil) and increased from Sep. 2025 (₹2,952 Mil) to Mar. 2026 (₹3,392 Mil).

Remus Pharmaceuticals's annual Other Stockholders Equity increased from Mar. 2024 (₹720 Mil) to Mar. 2025 (₹1,424 Mil) and increased from Mar. 2025 (₹1,424 Mil) to Mar. 2026 (₹3,392 Mil).

Remus Pharmaceuticals Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Remus Pharmaceuticals's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Remus Pharmaceuticals Other Stockholders Equity Chart

Remus Pharmaceuticals Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Stockholders Equity
Get a 7-Day Free Trial 54.32 0.40 720.40 1,423.50 3,392.10

Remus Pharmaceuticals Semi-Annual Data
Mar20 Mar21 Mar22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only 720.40 945.96 1,423.50 2,952.10 3,392.10
NSE:REMUS
53GF Score
Remus Pharmaceuticals Ltd NSE:REMUS
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Remus Pharmaceuticals Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of ₹3,392 Mil mean?
Remus Pharmaceuticals (NSE:REMUS) has a Other Stockholders Equity of ₹3,392 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Remus Pharmaceuticals and its competitors.
Is Remus Pharmaceuticals' Other Stockholders Equity too high?
Remus Pharmaceuticals' current Other Stockholders Equity is ₹3,392 Mil. Overall, Remus Pharmaceuticals has a GF Score™ of 53/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Remus Pharmaceuticals' Other Stockholders Equity compare to MCK and CAH?
Remus Pharmaceuticals' Other Stockholders Equity of ₹3,392 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Medical Distribution company?
A good Other Stockholders Equity depends on the Medical Distribution industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Remus Pharmaceuticals and its competitors. Remus Pharmaceuticals's current Other Stockholders Equity is ₹3,392 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Remus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Remus Pharmaceuticals (NSE:REMUS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹2,071.36, compared to a current price of ₹739.55 — trading 64.3% below its estimated fair value. The current Other Stockholders Equity is ₹3,392 Mil. Remus Pharmaceuticals' overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Remus Pharmaceuticals (NSE:REMUS), the current Other Stockholders Equity is ₹3,392 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Remus Pharmaceuticals (NSE:REMUS) Overvalued in 2026?

Based on GuruFocus' analysis, Remus Pharmaceuticals stock appears to be undervalued. The current stock price of ₹739.55 is trading 64.3% below its estimated GF Value™ of ₹2,071.36. GuruFocus considers Remus Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for NSE:REMUS:

  • Other Stockholders Equity: ₹3,392 Mil
  • GF Value™: ₹2,071.36 vs. price of ₹739.55 (64.3% below fair value)
  • GF Score™: 53/100 with 2 warning signs

No single metric tells the full story. See the NSE:REMUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Remus Pharmaceuticals Business Description

Address Ambli bopal Road, 1101 to 1103, South Tower, One 42, Behind Ashok Vatika, Near Jayantilal Park BRTS, Ahmedabad, GJ, IND, 380054
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
53GF Score

Get the complete analysis for NSE:REMUS

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹739.55
Price
₹2,071.36
GF Value